Charles Schwab Investment Management Inc Verastem, Inc. Transaction History

Charles Schwab Investment Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.33 - $10.44 $3,511 - $111,081	10,640 Added 14.14%	85,909 $34,000
Q2 2022 Aug 15, 2022	SELL	$1.02 - $1.83 $392,928 - $704,959	-385,224 Reduced 83.65%	75,269 $88,000
Q1 2022 May 13, 2022	BUY	$1.06 - $2.1 $11,755 - $23,289	11,090 Added 2.47%	460,493 $650,000
Q3 2021 Nov 16, 2021	BUY	$2.54 - $4.07 $72,024 - $115,408	28,356 Added 6.73%	449,403 $1.39 Million
Q2 2021 Aug 16, 2021	SELL	$2.57 - $4.85 $32,232 - $60,828	-12,542 Reduced 2.89%	421,047 $1.71 Million
Q1 2021 May 17, 2021	BUY	$1.9 - $2.82 $60,722 - $90,124	31,959 Added 7.96%	433,589 $1.07 Million
Q4 2020 Feb 16, 2021	BUY	$1.15 - $2.4 $1,557 - $3,249	1,354 Added 0.34%	401,630 $856,000
Q2 2020 Aug 14, 2020	BUY	$1.69 - $4.2 $676,466 - $1.68 Million	400,276 New	400,276 $689,000
Q2 2019 Aug 09, 2019	SELL	$1.25 - $3.14 $179,623 - $451,214	-143,699 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$2.79 - $4.09 $32,045 - $46,977	-11,486 Reduced 7.4%	143,699 $426,000
Q3 2018 Nov 13, 2018	BUY	$6.86 - $9.97 $279,942 - $406,855	40,808 Added 35.68%	155,185 $1.13 Million
Q2 2018 Aug 08, 2018	BUY	$2.88 - $8.67 $329,405 - $991,648	114,377 New	114,377 $787,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $838M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.